| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2005 | EP1551812A2 Mitotic kinesin inhibitors |
| 07/13/2005 | EP1551809A1 Pyrazole compounds for treatment of neurodegenerative disorders |
| 07/13/2005 | EP1551805A1 Substituted gamma-phenyl-delta-lactams and uses related thereto |
| 07/13/2005 | EP1551803A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 07/13/2005 | EP1551802A1 Indole-3-sulphur derivatives |
| 07/13/2005 | EP1551801A1 Novel gamma-lactams as beta-secretase inhibitors |
| 07/13/2005 | EP1551800A1 Pyrrolidine derivatives for use in treating hepatitis c virus infection |
| 07/13/2005 | EP1551799A1 Cyclohexyl sulphones as gamma-secretase inhibitors |
| 07/13/2005 | EP1551795A1 Inhibitors of histone deacetylase |
| 07/13/2005 | EP1551794A1 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 07/13/2005 | EP1551793A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 07/13/2005 | EP1551792A1 Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments |
| 07/13/2005 | EP1551791A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 07/13/2005 | EP1551790A2 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 07/13/2005 | EP1551511A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 07/13/2005 | EP1551495A2 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551460A1 A method for monitoring the effectiveness of tetracycline in the treatment of asthma |
| 07/13/2005 | EP1551457A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 07/13/2005 | EP1551455A2 Product and process for liquefaction of mucus or sputum |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551445A2 Use of il-2 receptor antibodies to prevent toxicity associated with amphotericin b antimycotic therapy |
| 07/13/2005 | EP1551440A2 Uses of human zven proteins and polynucleotides |
| 07/13/2005 | EP1551434A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/13/2005 | EP1551429A2 Antiseptic solutions containing silver chelated with polypectate and edta |
| 07/13/2005 | EP1551428A2 Polymer compositions containing bioactive agents and methods for their use |
| 07/13/2005 | EP1551427A1 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| 07/13/2005 | EP1551426A2 Methods of administering fgf18 |
| 07/13/2005 | EP1551425A2 Therapeutic formulations |
| 07/13/2005 | EP1551424A1 Treatment of neurological disorders by dsrna adminitration |
| 07/13/2005 | EP1551423A1 Compositions comprising highly purified amphotericin b |
| 07/13/2005 | EP1551422A1 Carbohydrate based anti-bacterials |
| 07/13/2005 | EP1551421A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/13/2005 | EP1551420A1 Aryl phosphate derivatives with selective activity against adenovirus and hiv |
| 07/13/2005 | EP1551419A2 Relief of aids symptoms |
| 07/13/2005 | EP1551417A2 Three layer tear formulation |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551415A1 Pharmaceutical application of 15- or 16- substituted testosterone analogues |
| 07/13/2005 | EP1551414A2 Crystal forms of olanzapine and processes for their preparation |
| 07/13/2005 | EP1551413A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551411A2 Synergistic methods and compositions for treating cancer |
| 07/13/2005 | EP1551409A1 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 07/13/2005 | EP1551408A1 4-(4-methylpiperazin-1-ylmethyl)-n- 4-pyridin-3-yl)pyrimidin -2-ylamino)phenyl -benzamide for treating anaplastic thyroid cancer |
| 07/13/2005 | EP1551407A1 Treatment of aml |
| 07/13/2005 | EP1551406A1 Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis |
| 07/13/2005 | EP1551405A1 Tiotropium salts for reducing respiratory mortality rate |
| 07/13/2005 | EP1551404A2 Method of inhibiting angiogenesis |
| 07/13/2005 | EP1551402A2 Abuse-resistant pharmaceutical compositions |
| 07/13/2005 | EP1551401A2 Mannitol formulation for integrin receptor antagonist |
| 07/13/2005 | EP1551400A2 Preparation of triazospiro compounds |
| 07/13/2005 | EP1551399A1 Method for topical treatment of eye disease and composition and device for said treatment |
| 07/13/2005 | EP1551398A1 Pyrazolopyridines and methods of making and using the same |
| 07/13/2005 | EP1551397A2 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/13/2005 | EP1551396A1 Pin1-modulating compounds and methods of use thereof |
| 07/13/2005 | EP1551395A1 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist |
| 07/13/2005 | EP1551394A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 07/13/2005 | EP1551393A2 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 07/13/2005 | EP1551392A2 Novel lapacho compounds and methods of use thereof |
| 07/13/2005 | EP1551391A1 Dry syrup preparation of procaterol comprising ascorbinic acid and citric acid |
| 07/13/2005 | EP1551390A1 Levamisole, avermectins or similar in pyrrolidone solvent |
| 07/13/2005 | EP1551389A2 Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| 07/13/2005 | EP1551388A2 Compounds useful for the treatment of cancer, compositions thereof and methods therewith |
| 07/13/2005 | EP1551387A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/13/2005 | EP1551386A2 Methods and compositions for the treatment of lupus using clofarabine |
| 07/13/2005 | EP1551385A2 Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| 07/13/2005 | EP1551383A2 Methods for preventing and treating microbial infections by modulating transcription factors |
| 07/13/2005 | EP1551382A2 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 07/13/2005 | EP1551381A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 07/13/2005 | EP1551380A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 07/13/2005 | EP1551379A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/13/2005 | EP1551378A2 Epo d + 5-fu/gemcitabine |
| 07/13/2005 | EP1551376A2 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 07/13/2005 | EP1551371A2 Stabilized nanoparticle formulations of camptotheca derivatives |
| 07/13/2005 | EP1551370A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 07/13/2005 | EP1551369A2 Combination therapy for treatment of fibrotic disorders |
| 07/13/2005 | EP1551361A1 Oral composition providing enhanced oral hygiene properties |
| 07/13/2005 | EP1551357A2 Group b streptococcus vaccine |
| 07/13/2005 | EP1551356A2 Pravastatin pharmaceutical formulations and methods of their use |
| 07/13/2005 | EP1551341A2 Use of y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation |
| 07/13/2005 | EP1551228A2 Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| 07/13/2005 | EP1487418A4 Co-beadlet of dha and rosemary and methods of use |
| 07/13/2005 | EP1448529B1 Sulfone derivatives suitable for the treatment of autoimmune diseases and allergies |
| 07/13/2005 | EP1432379A4 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 07/13/2005 | EP1427711B1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 07/13/2005 | EP1357898A4 Improved controlled release oral dosage form |
| 07/13/2005 | EP1315695B1 Benzene tricarboxylic acid amides as insulin receptor activators |
| 07/13/2005 | EP1248636B1 Dextrin containing compositions for prevention of adhesions |
| 07/13/2005 | EP1235802B1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 07/13/2005 | EP1202722B1 Uses of compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 07/13/2005 | EP1178969B1 Gastrin and cholecystokinin receptor ligands |
| 07/13/2005 | EP1171443B1 Bicyclic heteroaromatic compounds useful as lh agonists |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1152756B1 Anticonvulsant derivatives useful in treating autism |
| 07/13/2005 | EP1144364B1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/13/2005 | EP1119363B1 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 07/13/2005 | EP1113795B1 Tryptophanyl esters and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/13/2005 | EP1042291B1 Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents |
| 07/13/2005 | EP1030567B1 System for dialysis and shock treatment |
| 07/13/2005 | EP1020426B1 Amine derivatives and process for producing the same |